Leslie Donato, Ph.D., DABCC, Co-Director of the Cardiovascular Laboratory Medicine and Co-Director of the Hospital Clinical Laboratory and Point-of-Care Testing at Mayo Clinic in Rochester, recently authored an article in Clinical Laboratory News on irritable bowel syndrome.
This week’s Research Roundup highlights autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease.
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
Mayo Clinic has completed validation of its existing Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum test for the new biosimilar drug Inflectra. Clients can ...
The differential diagnosis for inflammatory bowel disease (IBD) includes irritable bowel syndrome (IBS). While the clinical presentation is similar, IBD is an inflammatory disease, while IBS is a noninflammatory disease. View this "Hot Topic" to learn about testing for IBD and IBS.
The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.
Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.